Publisher
Springer International Publishing
Reference12 articles.
1. Agache I, Song Y, Rocha C, Beltran J, Posso M, Steiner C et al (2020) Efficacy and safety of treatment with dupilumab for severe asthma: a systematic review of the EAACI guidelines-recommendations on the use of biologicals in severe asthma. Allergy 75:1058–1068. https://doi.org/10.1111/all.14268
2. Blauvelt A, Papp KA, Griffiths CEM et al (2017) Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 76:405–417
3. El Dib R, Gomaa H, Carvalho RP, Camargo SE, Bazan R, Barretti P, Barreto FC (2017) Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev 7:CD006663
4. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S et al (2001) Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry’s disease. N Engl J Med 345:9–16
5. Garegnani L, Styrmisdóttir L, Roson Rodriguez P, Escobar Liquitay CM, Esteban I, Franco JVA (2021) Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane Database Syst Rev 11:CD013757